Alpinetin Targets Mitophagy Pathways to Mitigate Parkinson's Disease Progression
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1002/cns.70676 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Zilu Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Anesthesiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China. Hauptthemen laut MEDLINE: Mitophagy, Flavanones, Neuroprotective Agents, Parkinson Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province, Jiangxi Provincial Outstanding Young Talent Fund.
Abstract (Originalsprache)
Aims
Parkinson's disease (PD) is a complex neurodegenerative disorder lacking disease‐modifying therapies. This study aimed to systematically investigate the therapeutic potential and underlying mechanisms of Alpinetin in PD.
Methods
An integrated approach combining network pharmacology and molecular docking was employed to predict the core targets and pathways of Alpinetin in PD. These computational predictions were subsequently validated through in vivo animal experiments.
Results
Network pharmacology analysis predicted that Alpinetin exerts its effects by modulating mitophagy and dopaminergic synaptic pathways. Molecular docking revealed strong binding affinities between Alpinetin and key targets, including HIF1A, SQSTM1, and SRC. Guided by these findings, animal experiments confirmed the neuroprotective effects of Alpinetin, aligning with the predicted mechanisms.
Conclusion
Our findings demonstrate that Alpinetin has significant therapeutic potential for PD, likely mediated through the regulation of mitophagy and dopaminergic synapses. This study elucidates the molecular targets and mechanisms of Alpinetin, providing a solid foundation for its further investigation as an anti‐PD agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Anesthesiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China.
- The Second Clinical Medical College of Nanchang University, Nanchang, Jiangxi Province, China.
- Jiangxi Province Key Laboratory of Anesthesiology, Nanchang, Jiangxi Province, China.
- Department of Neurosurgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
ORCID-Profile: Lieliang Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
- Jiangxi Provincial Outstanding Young Talent Fund
Zitieren
APA
Shen, Z., Shan, X., Zhang, S., Huang, D., Hu, H., Liang, Y., Zhu, H., Zhang, L., & Chen, Y. (2025). Alpinetin Targets Mitophagy Pathways to Mitigate Parkinson's Disease Progression. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70676
Vancouver
Shen Z, Shan X, Zhang S, Huang D, Hu H, Liang Y, et al. Alpinetin Targets Mitophagy Pathways to Mitigate Parkinson's Disease Progression. CNS Neuroscience & Therapeutics. 2025. doi:10.1002/cns.70676
BibTeX
@article{Shen2025,
author = {Shen, Zilu and Shan, Xuesong and Zhang, Shenglan and Huang, Dan and Hu, Haijun and Liang, Yonglin and Zhu, Hong and Zhang, Lieliang and Chen, Yayu},
title = {Alpinetin Targets Mitophagy Pathways to Mitigate Parkinson's Disease Progression},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1002/cns.70676}
}
EUVIMED